GANX - Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

2024-05-29 18:15:11 ET

Summary

• Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease.
• Gain is progressing at an impressive speed through its Phase 1 trial.
• Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors.
• Gain Therapeutics is considerably undervalued compared to peers and recent acquisition targets in the neurodegenerative space.

Thesis

I covered Gain Therapeutics, Inc. ( GANX ) some months ago, having found both the company’s drug-discovery platform Magellan and drug candidate GT-02287, the second drug candidate with best-in-class potential which has been generated by that platform, fascinating.

I believe GT-02287 may be able to slow or stop disease progression by a disease-modifying mechanism, contrary to current therapies which are only symptomatic.

I am returning to coverage of the company because Gain is at a pivotal moment in its progression, and because the recent dip presents a good buying opportunity. Gain’s stock has been volatile lately, having seen gains of +40% since my initial coverage, but now trading -30% below....

For further details see: